If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
7don MSN
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results